Tricida, Inc. is a late-stage pharmaceutical company focused on the discovery and clinical development of non-absorbed therapeutics to address renal, metabolic and cardiovascular disease. The Company’s lead program, TRC101 is a treatment for chronic kidney disease (CKD). The Company is engaged in developing a non-absorbed drug to enable safety and efficacy for chronic treatment of CKD patients. The TRC101 drug acts in the gastrointestinal tract and clears the human body through the digestive system, by preventing degradation and systemic uptake.
Market Cap:1800M; Shares Outstanding:49.8M; Short Interest: 8.46%; Q3 2019(9/30/19): Cash 322M. Loss 44.48M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
Total institutions: 118，no change
Shares hold: 39698k shares. no change
shares% hold: 30.01%，no change